LAVAL, Quebec– (BUSINESS WIRE) – Altasciences is verheugd ReAlta Life Sciences te ondersteunen door een Fase I-studie uit te voeren om RLS-0071 te evalueren voor de behandeling van acute longschade (ALI) als gevolg van virale infecties, zoals COVID-19, respiratoir syncytieel virus (RSV) en influenza. Als onderdeel van het lopende ReAlta ALI-programma is de Fase I-studie een gerandomiseerde, dubbelblinde, placebogecontroleerde, adaptieve studie met enkelvoudige oplopende dosis om de veiligheid, verdraagbaarheid, PK en PD van RLS-0071 in gezonde proefpersonen, uitgevoerd op de afdeling klinische farmacologie van Altasciences in Montreal, Canada.

Ingrid Holmes, Vice President, Global Clinical Operations bij Altasciences, zegt: “Onze teams zijn er trots op dat ze de kans hebben gekregen om betrokken te zijn bij de klinische uitvoering en bioanalytische analyse voor deze belangrijke eerste proef bij mensen. Prioriteit kunnen geven aan COVID-19-therapieën door cruciale gegevens bij te dragen aan de ontwikkeling van mogelijk levensveranderende medicijnen, zoals RLS-0071, is enorm lonend voor onze teams.”

Altasciences Conducts Phase I Study in Healthy Normal Subjects for RLS-0071 for Treatment of Acute Lung Injury Due to COVID-19 Pneumonia

LAVAL, Quebec–(BUSINESS WIRE)– Altasciences is pleased to support ReAlta Life Sciences by conducting a Phase I trial to evaluate RLS-0071 for treatment of Acute Lung Injury (ALI) as a result of viral infections, such as COVID-19, respiratory syncytial virus (RSV), and influenza. As part of the ReAlta ALI program underway, the Phase I trial is a single-ascending dose, randomized, double-blind, placebo-controlled, adaptive-design study to evaluate the safety, tolerability, PK, and PD of RLS-0071 in healthy subjects, performed at the Altasciences clinical pharmacology unit in Montreal, Canada.

Ingrid Holmes, Vice President, Global Clinical Operations at Altasciences, says, “Our teams are proud to have the opportunity to be involved in the clinical conduct and bioanalytical analysis for this important first-in-human trial. Being able to prioritize COVID-19 therapies by contributing critical data to the development of potentially life-altering medications, such as RLS-0071, is tremendously rewarding to our teams.”

Click here to read the ReAlta press release on RLS-0071, and to learn more about ReAlta Life Sciences.

“The results from our healthy volunteers study will inform our ongoing ALI study in hospitalized COVID-19 patients, as well as future programs … we look forward to obtaining data from this study as it progresses to market,” says Ulrich Thienel, M.D., Ph.D., ReAlta’s Chief Executive Officer.

About Altasciences

Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005644/en/

Contacts

Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com